Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis.
Calleja JL, Pascasio JM, Ruiz-Antoran B, Gea F, Barcena R, Larrubia JR, Perez-Alvarez R, Sousa JM, Romero-Gomez M, Sola R, de la Revilla J, Crespo J, Navarro JM, Arenas JI, Delgado M, Fernandez-Rodriguez CM, Planas R, Buti M, Forns X.Spanish Grp Study Use.
Liver Int. 2015; 35: 90-100. FI: 4.850 (Q1).
Effectiveness of Adalimumab in Perianal Fistulas in Crohn’s Disease Patients Naive to Anti-TNF Therapy.
Castano-Milla C, Chaparro M, Saro C, Barreiro-de Acosta M, Garcia-Albert AM, Bujanda L, Martin-Arranz MD, Carpio D, Munoz F, Mancenido N, Garcia-Planella E, Piqueras M, Calvet X, Cabriada JL, Botella B, Bermejo F, Gisbert JP.
J. Clin. Gastroenterol. 2015; 49: 34-40. FI: 3.498 (Q2).
Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities.
Buti M, Morillas RM, Perez J, Prieto M, Sola R, Palau A, Diago M, Bonet L, Gallego A, Garcia-Samaniego J, Testillano M, Rodriguez M, Castellano G, Gutierrez ML, Delgado M, Mas A, Romero-Gomez M, Calleja JL, Gonzalez-Guirado A, Arenas JI, Garcia-Buey L, Andrade R, Gila A, ORIENTE-2 Study Grp.
Eur. J. Gastroenterol. Hepatol. 2015; 27: 46-54. FI: 2.253 (Q3).
Comparison of Val81Met and other polymorphisms of alcohol metabolising genes in patients and controls in Northern Spain.
Celorrio D, Bujanda L, Caso C, Landabaso M, Carlos O, Ogando J, De Pancorbo Marian MA.
Alcohol. 2012; 46: 427-431. FI: 2.468 (Q2).
A High Degree of LINE-1 Hypomethylation Is a Unique Feature of Early-Onset Colorectal Cancer.
Antelo M, Balaguer F, Shia J, Shen Y, Hur K, Moreira L, Cuatrecasas M, Bujanda L, Giraldez MD, Takahashi M, Cabanne A, Barugel ME, Mil LA, Roca E, Andreu M, Castellvi-Bel S, Llor X, Jover R, Castells A, Boland CR, Goel A.
PLoS One. 2012; 7: -0. FI: 4.092 (Q1).
Accurate fat fraction quantification by multiecho gradient-recalled-echo magnetic resonance at 1.5 T in rats with nonalcoholic fatty liver disease.
Hijona E, Sanchez-Gonzalez J, Alustiza JM, Hijona L, Arenas J, Garcia E, Rojas N, Portillo MP, Jimenez R, Aldazabal P, Bujanda L.
Eur. J. Radiol. 2012; 81: 1122-1127. FI: 2.606 (Q2).
Adjuvant and neoadjuvant treatment in pancreatic cancer.
Herreros-Villanueva M, Hijona El, Cosme A, Bujanda L.
World J. Gastroenterol. 2012; 18: 1565-1572. FI: 2.471 (Q2).
Association of alcohol dehydrogenase polymorphisms and life-style factors with excessive alcohol intake within the Spanish population (EPIC-Spain).
Munoz X, Amiano P, Celorrio D, Dorronsoro M, Sanchez MJ, Huerta JM, Barricarte A, Navarro C, Molina-Montes E, Chirlaque MD, Ardanaz E, Rodriguez L, Duell EJ, Sala N, Bujanda L.
Addiction. 2012; 107: 2117-2127. FI: 4.313 (Q1).
FATT Collaborative Grp. Autologous Expanded Adipose-Derived Stem Cells for the Treatment of Complex Cryptoglandular Perianal Fistulas: A Phase III Randomized Clinical Trial (FATT 1: Fistula Advanced Therapy Trial 1) and Long-term Evaluation.
Herreros MD, Garcia-Arranz M, Guadalajara H, De-La-Quintana P, Garcia-Olmo D.
Dis. Colon Rectum. 2012; 55: 762-772. FI: 3.132 (Q1).
Changes in the levels of thioredoxin and indoleamine-2, 3-dioxygenase activity in plasma of patients with colorectal cancer treated with chemotherapy.
Cavia-Saiz M, Muniz P, De Santiago R, Herreros-Villanueva M, Garcia-Giron C, Lopez AS, Coma-del Corral MJ.
Biochem. Cell Biol. 2012; 90: 173-178. FI: 2.673 (Q3).
C-Met in pancreatic cancer stem cells: Therapeutic implications.
Zubia-Olascoaga A, Bujanda L.
World J. Gastroenterol. 2012; 18: 5321-5323. FI: 2.471 (Q2).
Colonprev. Study Investigators, Spanish Gastroenterological Assoc. Colonoscopy versus Fecal Immunochemical Testing in Colorectal-Cancer Screening.
Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas A, Andreu M, Carballo F, Morillas JD, Hernandez C, Jover R, Montalvo I, Arenas J, Laredo E, Hernandez V, Iglesias F, Cid E, Zubizarreta R, Sala T, Ponce M, Andres M, Teruel G, Peris A, Roncales MP, Polo-Tomas M, Bessa X, Ferrer-Armengou O, Grau J, Serradesanferm A, Ono A, Cruzado J, Perez-Riquelme F, Alonso-Abreu I, De la Vega-Prieto M, Reyes-Melian JM, Cacho G, Diaz-Tasende J, Herreros de Tejada A, Poves C, Santander C, Gonzalez-Navarro A.
N. Engl. J. Med. 2012; 366: 697-706. FI: 53.298 (Q1).
Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.
Perez-Carbonell L, Ruiz-Ponte C, Guarinos C, Alenda C, Paya A, Brea A, Egoavil CM, Castillejo A, Barbera VM, Bessa X, Xicola RM, Rodriguez-Soler M, Sanchez-Fortun C, Acame N, Castellvi-Bel, S, Pinol V, Balaguer F, Bujanda L, De-Castro ML, Llor X, Andreu M, Carracedo A, Soto JL, Castells A, Jover R.
Gut. 2012; 61: 865-872. FI: 10.111 (Q1).
Effect of Neoadjuvant Chemotherapy in Hepatic Steatosis.
Jimenez R, Hijona E, Emparanza J, Alustiza JM, Hijona L, Macarulla, MT, Portillo MP, Herreros-Villanueva M, Beguiristain A, Arenas J, Bujanda L.
Chemotherapy. 2012; 58: 89-94. FI: 1.816 (Q3).
